As of 2025-06-20, the Intrinsic Value of Biomarin Pharmaceutical Inc (BMRN) is 83.86 USD. This Biomarin valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 55.24 USD, the upside of Biomarin Pharmaceutical Inc is 51.80%.
The range of the Intrinsic Value is 53.32 - 225.02 USD
Based on its market price of 55.24 USD and our intrinsic valuation, Biomarin Pharmaceutical Inc (BMRN) is undervalued by 51.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 53.32 - 225.02 | 83.86 | 51.8% |
| DCF (Growth 10y) | 72.12 - 293.72 | 111.76 | 102.3% |
| DCF (EBITDA 5y) | 56.22 - 76.56 | 67.76 | 22.7% |
| DCF (EBITDA 10y) | 70.67 - 100.09 | 86.24 | 56.1% |
| Fair Value | 68.29 - 68.29 | 68.29 | 23.63% |
| P/E | 48.24 - 70.18 | 58.71 | 6.3% |
| EV/EBITDA | 49.64 - 65.06 | 58.15 | 5.3% |
| EPV | 20.06 - 25.90 | 22.98 | -58.4% |
| DDM - Stable | 35.66 - 197.17 | 116.42 | 110.7% |
| DDM - Multi | 58.28 - 252.39 | 94.92 | 71.8% |
| Market Cap (mil) | 10,593.93 |
| Beta | 0.52 |
| Outstanding shares (mil) | 191.78 |
| Enterprise Value (mil) | 10,140.77 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.30% |
| Cost of Debt | 4.25% |
| WACC | 7.12% |